The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XII.k

Constrictive pericarditis - Pericardial thickening

Publications

Tintner R, Manian P, Gauthier P, Jankovic J

Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease.

Archives of neurology. 2005;62(8):1290-5

Balachandran KP, Stewart D, Berg GA, Oldroyd KG

Chronic pericardial constriction linked to the antiparkinsonian dopamine agonist pergolide.

Postgraduate medical journal. 2002;78(915):49-50

Shaunak S, Wilkins A, Pilling JB, Dick DJ

Pericardial, retroperitoneal, and pleural fibrosis induced by pergolide.

Journal of neurology, neurosurgery, and psychiatry. 1999;66(1):79-81